217 related articles for article (PubMed ID: 17454792)
1. Clinical, radiological, and pathological findings in four children with gastrointestinal stromal tumors of the stomach.
Sauseng W; Benesch M; Lackner H; Urban C; Kronberger M; Gadner H; Höllwarth M; Spuller E; Aschauer M; Horcher E
Pediatr Hematol Oncol; 2007; 24(3):209-19. PubMed ID: 17454792
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
4. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal stromal tumors of the stomach.
Bennett JJ; Rubino MS
Surg Oncol Clin N Am; 2012 Jan; 21(1):21-33. PubMed ID: 22098829
[TBL] [Abstract][Full Text] [Related]
6. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
Kleinbaum EP; Lazar AJ; Tamborini E; Mcauliffe JC; Sylvestre PB; Sunnenberg TD; Strong L; Chen LL; Choi H; Benjamin RS; Zhang W; Trent JC
Int J Cancer; 2008 Feb; 122(3):711-8. PubMed ID: 17943734
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography.
Lassau N; Lamuraglia M; Chami L; Leclère J; Bonvalot S; Terrier P; Roche A; Le Cesne A
AJR Am J Roentgenol; 2006 Nov; 187(5):1267-73. PubMed ID: 17056915
[TBL] [Abstract][Full Text] [Related]
8. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
9. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
10. Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case.
Tsuneoka N; Kuroki T; Haraguchi M; Furui J
Surg Today; 2006; 36(11):989-93. PubMed ID: 17072721
[TBL] [Abstract][Full Text] [Related]
11. [The diagnostic and predictive role of kit (CD117)].
Dirnhofer S; Zimpfer A; Went P
Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
[TBL] [Abstract][Full Text] [Related]
12. Imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
[TBL] [Abstract][Full Text] [Related]
13. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
14. High-risk CD117-positive gastrointestinal stromal tumor of the colon in a 12-year-old girl: adjuvant treatment with imatinib mesylate.
Okur A; Oguz A; Karadeniz C; Pinarli FG; Ozen O; Ekinci O
Tumori; 2012; 98(2):59e-62e. PubMed ID: 22678007
[TBL] [Abstract][Full Text] [Related]
15. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy.
Melichar B; Voboril Z; Nozicka J; Ryska A; Urminská H; Vanecek T; Michal M
Intern Med; 2005 Nov; 44(11):1163-8. PubMed ID: 16357454
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
17. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
[TBL] [Abstract][Full Text] [Related]
18. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]